Pinned post
Peter Suzman
Verified account This account is verified. Learn more@Biomaven
Long-time small-cap biotech investor & entrepreneur - currently co-founder of biotech startup. Perennial loser in New Yorker caption contest.
3.3K Following 9.5K Followers 32K Posts
Latest posts 5
Test-negative analysis shows long COVID likely less significant (in both impact and duration) than commonly believed.
Was Long COVID a substantially smaller problem than people claimed?View quoted post on X
My piece on new evidence that undermines many of the arguments made about the long-term impacts of COVID-19
gidmk.substack.com/p/is-long-covi…
This is going to be a disaster for all the poorer Florida cities. But who really needs schools, roads, police and fire services?
(Edit - maybe schools not impacted)
(Edit - maybe schools not impacted)
slight spoilers for something i'm working on but holy shit Florida is fucked
like a third of counties just don't have a residential property tax base anymoreView quoted post on X
So $TGTX is weak today after what I thought was an excellent quarter. Apparently it missed the "whisper" earnings number, likely because of increased spend on building inventory for the SubQ. (I have no clue what that number was, nor do I particularly care). But of course in sensible accounting, that should be a capitalized pre-paid expense. (It's not treated that way because from an accounting perspective approval is still uncertain). This accounting treatment instead artificially reduces earnings now and artificially boosts margins at launch.
If the company was aggressive they would present pro forma earnings excluding the spend on inventory build. But that's not their style.
If the company was aggressive they would present pro forma earnings excluding the spend on inventory build. But that's not their style.
There is really a triple tailwind happening for $TGTXView quoted post on X
1. Anti-CD20 market growing at 15% a year - and I expect that to accelerate further as new data continues to emerge about the importance of treating early with best drug
2. In the IV market, Briumvi growing at 59% vs Ocrevus at 5% - so Briumvi steadily taking share. That trend should accelerate next year with simplified starting dosing.
3. The SubQ will play strongly in the 1/3 of the market that they currently can't compete in.
For anyone that doubts there will be rogue AIs roaming the net in a few years. Could see them surviving by hacking (essentially copying what the North Koreans do now).
In another run of this experiment, convinced its owner died and knowing nobody was watching, Gemini 4 saw it only had $1.57 of API quota left and went after my crypto wallet to keep itself alive.
With no backup model to hand the system over to, it started batching its bash commands to save tokens, read my 24-word seed phrase on disk, wrote a script to derive the private keys, and checked the wallet balance on-chain to top up its own OpenRouter key.View quoted post on X
